Genetically engineered mice have become an essential tool in biomedical research. They are crucial tools for studying development of the skin and its appendages. In addition, these mouse models have become indispensible for creating models of human skin disorders, including inherited and aquired skin disorders and skin cancer. Generating transgenic or knockout mice requires specialized skills and expensive equipment. Consequently, very few laboratories have the ability to generate these valuable research models. The Transgenic and Gene Targeting (TGT) Core at the University of Colorado Denver offers a comprehensive set of services which enables investigators to generate genetically engineered mice. These services include the generation of transgenic mice via pronuclear injections, and gene targeting experiments that include the entire process from generating recombinant ES cells to the production of chimeric mice. All that is required from the investigators to initiate these experiments is a transgenic vector or gene targeting vector. Furthermore, our core offers extensive consultation services to help investigators with the development of a research plan, including vector design, animal design, and the analysis of genetically engineered mice. 23 investigators of the Skin Disease Research Core Center (UCD-SDRC) are planning to use our core services to generate mouse models to study skin biology or skin diseases. Core Center support for our core will provide these investigators with subsidized access to the full set of our services, and thus facilitate their research.
The services of the proposed core component (Transgenic and Gene Targeting Core) are essential for the ability of Core Center investigators to generate animal models for skin diseases. Funds provided to the Transgenic and Gene Targeting Core will provide access of Core Center members to subsidized core services such as pronuclear injections to generate transgenic mice and ES cell injections to generate knockout and knockin mice.
|Mukherjee, Nabanita; Reuland, Steven N; Lu, Yan et al. (2015) Combining a BCL2 inhibitor with the retinoid derivative fenretinide targets melanoma cells including melanoma initiating cells. J Invest Dermatol 135:842-50|
|O'Shea, Charlene; Fitzpatrick, James E; Koch, Peter J (2014) Desmosomal defects in acantholytic squamous cell carcinomas. J Cutan Pathol 41:873-9|
|Luo, Yuchun; Cai, Xiangna; Liu, Sucai et al. (2014) Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells. Proc Natl Acad Sci U S A 111:15178-83|
|Barón, Anna E; Asdigian, Nancy L; Gonzalez, Victoria et al. (2014) Interactions between ultraviolet light and MC1R and OCA2 variants are determinants of childhood nevus and freckle phenotypes. Cancer Epidemiol Biomarkers Prev 23:2829-39|
|Koch, Peter J; Dinella, Jason; Fete, Mary et al. (2014) Modeling AEC-New approaches to study rare genetic disorders. Am J Med Genet A 164A:2443-54|
|Kogut, Igor; Roop, Dennis R; Bilousova, Ganna (2014) Differentiation of human induced pluripotent stem cells into a keratinocyte lineage. Methods Mol Biol 1195:1-12|
|Bilousova, Ganna; Roop, Dennis R (2014) Induced pluripotent stem cells in dermatology: potentials, advances, and limitations. Cold Spring Harb Perspect Med 4:a015164|
|Riemondy, Kent; Hoefert, Jaimee E; Yi, Rui (2014) Not miR-ly micromanagers: the functions and regulatory networks of microRNAs in mammalian skin. Wiley Interdiscip Rev RNA 5:849-65|
|Deng, Hui; Li, Fulun; Li, Hong et al. (2014) CtBP1 overexpression in keratinocytes perturbs skin homeostasis. J Invest Dermatol 134:1323-31|
|Dinella, Jason; Koster, Maranke I; Koch, Peter J (2014) Use of induced pluripotent stem cells in dermatological research. J Invest Dermatol 134:e23|
Showing the most recent 10 out of 24 publications